Sacubitril-valsartan therapy in a patient with heart failure due to isolated left ventricular noncompaction: a case report and literature review
Abstract. Background:. Left ventricular noncompaction (LVNC) is a rare type of cardiomyopathy. The core clinical feature is heart failure that responds poorly to treatments. Case presentation:. A 58-year-old woman received various treatments (including metoprolol, benazepril, torasemide, spirolacton...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Health/LWW
2022-03-01
|
Series: | Cardiology Plus |
Online Access: | http://journals.lww.com/10.1097/CP9.0000000000000003 |
_version_ | 1798045115812413440 |
---|---|
author | Ya-Wei Yang Jun Yuan Jing-Fen Xing Min Fan |
author_facet | Ya-Wei Yang Jun Yuan Jing-Fen Xing Min Fan |
author_sort | Ya-Wei Yang |
collection | DOAJ |
description | Abstract. Background:. Left ventricular noncompaction (LVNC) is a rare type of cardiomyopathy. The core clinical feature is heart failure that responds poorly to treatments.
Case presentation:. A 58-year-old woman received various treatments (including metoprolol, benazepril, torasemide, spirolactone, and digoxin) for 4 years for LVNC, but responded poorly. Upon presentation, transthoracic echocardiogram (ECHO) showed 26% left ventricular ejection fraction (LVEF) and class IV diastolic dysfunction. Upon cardiac magnetic resonance imaging (CMRI), the ratio of noncompacted versus compacted myocardium was 3.9. She received guideline-recommended treatments that included sacubitril-valsartan (100 mg/day) in addition to β-blocker, torasemide, spirolactone, digoxin, and isosorbide. Symptoms and signs improved rapidly, and she was discharged 1 week later. Sacubitril-valsartan dosage was adjusted to 200 mg/day 4 weeks later. She remained in relatively good health thereafter. At the last follow-up 16 months later, LVEF was 51% on ECHO. CMRI showed the significantly reduced ratio of 2.8 in noncompacted versus compacted myocardium.
Conclusions:. Sacubitril-valsartan therapy may result in reverse remodeling and improve long-term outcomes in LVNC patients. |
first_indexed | 2024-04-11T23:15:19Z |
format | Article |
id | doaj.art-71bb39850bbf42bbaa4e6660dc744767 |
institution | Directory Open Access Journal |
issn | 2470-7511 2470-752X |
language | English |
last_indexed | 2024-04-11T23:15:19Z |
publishDate | 2022-03-01 |
publisher | Wolters Kluwer Health/LWW |
record_format | Article |
series | Cardiology Plus |
spelling | doaj.art-71bb39850bbf42bbaa4e6660dc7447672022-12-22T03:57:37ZengWolters Kluwer Health/LWWCardiology Plus2470-75112470-752X2022-03-0171565910.1097/CP9.0000000000000003202203000-00008Sacubitril-valsartan therapy in a patient with heart failure due to isolated left ventricular noncompaction: a case report and literature reviewYa-Wei YangJun YuanJing-Fen XingMin FanAbstract. Background:. Left ventricular noncompaction (LVNC) is a rare type of cardiomyopathy. The core clinical feature is heart failure that responds poorly to treatments. Case presentation:. A 58-year-old woman received various treatments (including metoprolol, benazepril, torasemide, spirolactone, and digoxin) for 4 years for LVNC, but responded poorly. Upon presentation, transthoracic echocardiogram (ECHO) showed 26% left ventricular ejection fraction (LVEF) and class IV diastolic dysfunction. Upon cardiac magnetic resonance imaging (CMRI), the ratio of noncompacted versus compacted myocardium was 3.9. She received guideline-recommended treatments that included sacubitril-valsartan (100 mg/day) in addition to β-blocker, torasemide, spirolactone, digoxin, and isosorbide. Symptoms and signs improved rapidly, and she was discharged 1 week later. Sacubitril-valsartan dosage was adjusted to 200 mg/day 4 weeks later. She remained in relatively good health thereafter. At the last follow-up 16 months later, LVEF was 51% on ECHO. CMRI showed the significantly reduced ratio of 2.8 in noncompacted versus compacted myocardium. Conclusions:. Sacubitril-valsartan therapy may result in reverse remodeling and improve long-term outcomes in LVNC patients.http://journals.lww.com/10.1097/CP9.0000000000000003 |
spellingShingle | Ya-Wei Yang Jun Yuan Jing-Fen Xing Min Fan Sacubitril-valsartan therapy in a patient with heart failure due to isolated left ventricular noncompaction: a case report and literature review Cardiology Plus |
title | Sacubitril-valsartan therapy in a patient with heart failure due to isolated left ventricular noncompaction: a case report and literature review |
title_full | Sacubitril-valsartan therapy in a patient with heart failure due to isolated left ventricular noncompaction: a case report and literature review |
title_fullStr | Sacubitril-valsartan therapy in a patient with heart failure due to isolated left ventricular noncompaction: a case report and literature review |
title_full_unstemmed | Sacubitril-valsartan therapy in a patient with heart failure due to isolated left ventricular noncompaction: a case report and literature review |
title_short | Sacubitril-valsartan therapy in a patient with heart failure due to isolated left ventricular noncompaction: a case report and literature review |
title_sort | sacubitril valsartan therapy in a patient with heart failure due to isolated left ventricular noncompaction a case report and literature review |
url | http://journals.lww.com/10.1097/CP9.0000000000000003 |
work_keys_str_mv | AT yaweiyang sacubitrilvalsartantherapyinapatientwithheartfailureduetoisolatedleftventricularnoncompactionacasereportandliteraturereview AT junyuan sacubitrilvalsartantherapyinapatientwithheartfailureduetoisolatedleftventricularnoncompactionacasereportandliteraturereview AT jingfenxing sacubitrilvalsartantherapyinapatientwithheartfailureduetoisolatedleftventricularnoncompactionacasereportandliteraturereview AT minfan sacubitrilvalsartantherapyinapatientwithheartfailureduetoisolatedleftventricularnoncompactionacasereportandliteraturereview |